Abstract
A novel, rapid, accurate, sensitive, precise, and stability-indicating reverse-phase ultra-performance liquid chromatographic (RP-UPLC) method was developed and validated for determination of related substances of S(−)Amlodipine and S(−)Metoprolol Succinate in fixed dose combination tablet dosage form. The chromatographic separation was achieved with the use of Acquity UPLC HSS T3, 1.8 μm, 2.1 × 100 mm analytical column at 45°C employing a gradient elution. Mobile phase consisting of mobile phase-A (solution containing 5.0 gm of sodium dihydrogen phosphate monohydrate per liter of water and Acetonitrile in the ratio of 95 : 5) and mobile phase-B (Acetonitrile) was used at a flow rate of 0.5 mL min−1 with injection volume of 10 μL and the detection was done at 232 nm using UV detector. The retention times of S(−)Metoprolol Succinate and S(−)Amlodipine were found to be 2.8 minutes and 8.1 minutes, respectively. During method validation all the parameters were evaluated as per ICH guidelines, which remained well within acceptable limits. This method can be used for the estimation of related substances of S(−)Amlodipine and S(−)Metoprolol Succinate in fixed dose combination tablet dosage form.
Highlights
The combination of calcium channel blocker, that is, S(−)Amlodipine Besilate (Figure 1), and β1-adrenoceptor blocker, that is, S(−)Metoprolol Succinate (Figure 2), is more effective for the treatment of exercise-induced angina pectoris than β-adrenoceptor blocker immunotherapy
The formulation is available as bilayer tablets containing S(−)Amlodipine Besilate as immediate release and S(−)Metoprolol Succinate as extended release
We found that there are some spectrophotometric methods available for simultaneous estimation of Amlodipine and Metoprolol in tablet dosage form [1, 2] and few high performance liquid chromatographic analytical methods are published for determination of Amlodipine Besilate and Metoprolol Succinate in combination of pharmaceutical formulations [3,4,5,6,7]; some analytical methods are available for estimation of Amlodipine and Metoprolol in tablets having Amlodipine as immediate release and Metoprolol as extended release [8]
Summary
The combination of calcium channel blocker, that is, S(−)Amlodipine Besilate (Figure 1), and β1-adrenoceptor blocker, that is, S(−)Metoprolol Succinate (Figure 2), is more effective for the treatment of exercise-induced angina pectoris than β-adrenoceptor blocker immunotherapy. We found that there are some spectrophotometric methods available for simultaneous estimation of Amlodipine and Metoprolol in tablet dosage form [1, 2] and few high performance liquid chromatographic analytical methods are published for determination of Amlodipine Besilate and Metoprolol Succinate in combination of pharmaceutical formulations [3,4,5,6,7]; some analytical methods are available for estimation of Amlodipine and Metoprolol in tablets having Amlodipine as immediate release and Metoprolol as extended release [8]. Best to our present knowledge, there is no stability-indicating UPLC method available or published for the determination of related substances of S(−)Amlodipine Besilate and S(−)Metoprolol Succinate in fixed dose combination tablet dosage form. The proposed method was effectively applied for the routine analysis and quality control (QC) analysis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
